Allena Pharmaceuticals Inc.
| NASDAQ: ALNA |
| Healthcare / Biotechnology / USA |
| 0.1190 | -0.0067 | -5.33% | Vol 1.94M | 1Y Perf -90.76% |
| Jun 28th, 2022 16:00 DELAYED |
| BID | 0.1190 | ASK | 0.1229 | ||
| Open | 0.1300 | Previous Close | 0.1257 | ||
| Pre-Market | - | After-Market | 0.24 | ||
| - - | 0.12 101.68% |
| Target Price | 0.50 | Analyst Rating | Hold 3.00 | |
| Potential % | 320.17 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 3.67 | Earnings Rating | Strong Buy | |
| Market Cap | 10.68M | Earnings Date | 9th Aug 2022 | |
| Alpha | -0.07 | Standard Deviation | 0.25 | |
| Beta | 1.99 |
Today's Price Range 0.11550.1300 | 52W Range 0.06831.45 | 5 Year PE Ratio Range -5.40-1.60 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 7.80% | ||
| 1 Month | 2.61% | ||
| 3 Months | -44.26% | ||
| 6 Months | -80.00% | ||
| 1 Year | -90.76% | ||
| 3 Years | -96.91% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -84.83 | |||
ROE last 12 Months | -288.91 | |||
ROA (5Y Avg) | -82.85 | |||
ROA last 12 Months | -162.93 | |||
ROC (5Y Avg) | -78.63 | |||
ROC last 12 Months | -191.76 | |||
Return on invested Capital Q | -50.05 | |||
Return on invested Capital Y | -31.53 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.20 | ||||
| 1.15 | ||||
| - | ||||
| - | ||||
| -0.20 | ||||
| -0.73 | ||||
| 0.96 | ||||
| 0.11 | ||||
| 9.81M | ||||
| Forward PE | -0.61 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.90 | ||||
| 2.00 | ||||
| 0.01 | ||||
| 0.46 | ||||
| -66.40 | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -0.20 | -0.13 | 35.00 |
| Q03 2021 | -0.18 | -0.17 | 5.56 |
| Q02 2021 | -0.20 | -0.24 | -20.00 |
| Q01 2021 | -0.21 | -0.21 | 0.00 |
| Q04 2020 | -0.18 | -0.24 | -33.33 |
| Q03 2020 | -0.21 | -0.22 | -4.76 |
| Q02 2020 | -0.29 | -0.26 | 10.34 |
| Q01 2020 | -0.43 | -0.31 | 27.91 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -0.06 | 50.00 | Positive |
| 9/2022 QR | -0.05 | 28.57 | Positive |
| 12/2022 FY | -0.32 | 13.51 | Positive |
| 12/2023 FY | -0.20 | 16.67 | Positive |
| Next Report Date | 9th Aug 2022 |
| Estimated EPS Next Report | -0.06 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.94M |
| Shares Outstanding | 89.77K |
| Shares Float | 106.61M |
| Trades Count | 1.71K |
| Dollar Volume | 235.98K |
| Avg. Volume | 7.16M |
| Avg. Weekly Volume | 3.61M |
| Avg. Monthly Volume | 7.59M |
| Avg. Quarterly Volume | 10.29M |
Allena Pharmaceuticals Inc. (NASDAQ: ALNA) stock closed at 0.1257 per share at the end of the most recent trading day (a 1.37% change compared to the prior day closing price) with a volume of 1.93M shares and market capitalization of 10.68M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 22 people. Allena Pharmaceuticals Inc. CEO is Louis Brenner.
The one-year performance of Allena Pharmaceuticals Inc. stock is -90.76%, while year-to-date (YTD) performance is -78.78%. ALNA stock has a five-year performance of %. Its 52-week range is between 0.0683 and 1.45, which gives ALNA stock a 52-week price range ratio of 3.67%
Allena Pharmaceuticals Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 1.15, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -162.93%, a ROC of -191.76% and a ROE of -288.91%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Allena Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.06 for the next earnings report. Allena Pharmaceuticals Inc.’s next earnings report date is 09th Aug 2022.
The consensus rating of Wall Street analysts for Allena Pharmaceuticals Inc. is Hold (3), with a target price of $0.5, which is +320.17% compared to the current price. The earnings rating for Allena Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Allena Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Allena Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 26.52, ATR14 : 0.02, CCI20 : 13.73, Chaikin Money Flow : -0.10, MACD : 0.00, Money Flow Index : 49.91, ROC : 6.08, RSI : 48.44, STOCH (14,3) : 31.93, STOCH RSI : 0.61, UO : 39.18, Williams %R : -68.07), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Allena Pharmaceuticals Inc. in the last 12-months were: Louis Brenner (Option Excercise at a value of $0), Louis Brenner (Sold 40 328 shares of value $32 666 )
Allena Pharmaceuticals Inc.
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
CEO: Louis Brenner
Telephone: +1 617 467-4577
Address: One Newton Executive Park, Newton 02462, MA, US
Number of employees: 22
TipRanks News for ALNA
Fri, 01 Apr 2022 16:31 GMT Allena Pharmaceuticals (ALNA) Receives a Hold from H.C. Wainwright
- TipRanks. All rights reserved.Wed, 05 Jan 2022 16:35 GMT Allena Pharmaceuticals (ALNA) Receives a Buy from B.Riley Financial
- TipRanks. All rights reserved.Wed, 05 Jan 2022 11:25 GMT Analysts Top Healthcare Picks: Allena Pharmaceuticals (ALNA), Unity Biotechnology (UBX)
- TipRanks. All rights reserved.Wed, 05 Jan 2022 11:15 GMT Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Allena Pharmaceuticals (ALNA) and Gritstone Oncology (GRTS)
- TipRanks. All rights reserved.
